Patent Issued for Targeting the TLK1/NEK1 axis in prostate cancer (USPTO 11826369).

A patent has been issued for a method of treating prostate cancer by targeting the TLK1/NEK1 axis. Prostate cancer is a common form of cancer in men, and current treatments often become ineffective over time. The patent describes the use of a pharmaceutical composition containing a TLK1B inhibitor and an antiandrogen to improve the benefits of androgen deprivation therapy and delay disease progression. The inventors suggest that this approach has the potential to prevent the development of castrate-resistant prostate cancer and improve patient outcomes. [Extracted from the article]